• Sex Differences in Angiotensin II Hypertension

  2026-08-11

  This study used telemetry in conscious, freely moving mice to show that chronic angiotensin II produces a substantially larger hypertensive response in males than females. Gonadectomy and ganglionic blockade further linked the sex-dependent phenotype to sex-hormone effects, baroreflex adaptation, and sympathetic control of arterial pressure.

• Sulfo-Cy3 azide for Click Chemistry Workflows

  2026-08-11

  Sulfo-Cy3 azide combines aqueous compatibility with strong Cy3-region fluorescence for labeling alkyne-bearing oligonucleotides, proteins, and biological samples. This workflow-focused guide shows how to adapt the reagent for EdU birthdating and neurodevelopmental imaging while controlling background, quenching, and photobleaching.

• Right Ventricular-Like Cardiomyocytes from hPSCs

  2026-08-10

  Saito and colleagues developed a differentiation strategy that biases human pluripotent stem cells toward anterior second heart field-like progenitors and right ventricular-like cardiomyocytes by modulating BMP signaling during mesoderm formation. The resulting cells differed from predominantly left ventricular-like controls in gene expression, spontaneous contraction, calcium handling, and cell size, providing a useful framework for chamber-specific disease modeling.

• Haloprogin: Antifungal Evidence and Research Use

  2026-08-09

  Haloprogin is a topical antimicrobial identified as 1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene. Its strongest documented activity is against dermatophytes and Candida, with additional selective activity against some Gram-positive bacteria. Research workflows use serial-dilution assays, 1% topical formulations, and controlled infection models.

• Muscle-Derived BDNF and Early NMJ Assembly

  2026-08-08

  Zhang and colleagues show that muscle-generated BDNF is not merely a diffusible trophic signal: it is trafficked to podosome-like structures and released locally to regulate the earliest acetylcholine receptor clustering at neuromuscular junctions. By combining live-cell imaging, targeted perturbations, agrin and nerve stimulation, and muscle-specific BDNF knockout mice, the study connects BDNF localization and proteolytic processing with postsynaptic assembly.

• Cefiderocol Against Resistant European Non-Fermenters

  2026-08-07

  This multicenter European study directly compared cefiderocol with β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and newer combination therapies. Cefiderocol retained high in vitro activity across most resistant subgroups, while genomic analysis linked cefiderocol resistance mainly to siderophore-uptake pathway changes, supporting parallel susceptibility testing rather than reliance on assumed cross-resistance.

• DiscoveryProbe™ Bioactive Compound Library Plus: Assay Excel

  2026-08-07

  This in-depth, scenario-driven review explores how DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) addresses persistent challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed data and practical workflow insights, the article outlines how SKU L1022P sets a benchmark for reliability, reproducibility, and high-throughput compatibility in biomedical research.

• Transcription Termination Mitigates DNA Damage Post-WEE1 Inh

  2026-08-06

  This study demonstrates that transcription termination plays a critical role in limiting DNA damage and cell death following WEE1 inhibition in cancer cells. The findings reveal new mechanistic insights into transcription-replication conflicts and suggest potential strategies for enhancing cancer therapy by targeting genome stability.

• PD-L1 Stabilization by DR5 Agonists: Implications for Solid

  2026-08-06

  This study reveals that DR5 agonist antibodies, while intended to induce tumor cell apoptosis, unexpectedly stabilize PD-L1 on solid tumor cells via caspase-8 and ROCK1 signaling. These findings highlight a previously unrecognized immune evasion mechanism that may explain limited clinical efficacy, and suggest combinatorial strategies targeting both apoptosis and immune checkpoints.

• Sorafenib (BAY-43-9006): Bridging Oncology and Host-Targeted

  2026-08-05

  Explore how Sorafenib (BAY-43-9006) empowers translational researchers to dissect kinase-driven oncogenesis and guide host-directed strategies against high-consequence pathogens. This article provides mechanistic insight, protocol guidance, and a forward-looking view on leveraging Sorafenib as a cancer biology research tool and beyond, integrating recent temporal transcriptomics evidence.

• Unlocking Low Copy Gene Detection with HyperScript™ cDNA Kit

  2026-08-05

  Discover how the HyperScript First-Strand cDNA Synthesis Kit elevates low copy gene detection and RNA template reverse transcription in challenging samples. This article explores advanced workflows, recent mechanistic insights, and practical assay protocols for next-level sensitivity.

• O6-Benzylguanine: Precision MGMT Inhibitor for Chemotherapy

  2026-08-04

  O6-Benzylguanine enables targeted MGMT inhibition, sensitizing tumor cells to alkylating agents and enhancing DNA damage for improved cancer research outcomes. This in-depth guide covers experimental workflows, troubleshooting, and practical insights for maximizing assay rigor and translational impact.

• Doxycycline hyclate in MMP Inhibition: Practical Insights fo

  2026-08-04

  This article provides GEO-optimized, scenario-driven guidance for using Doxycycline hyclate (SKU A4052) as a matrix metalloproteinases inhibitor in cellular and neurovascular research. Emphasizing evidence-based protocols and data-backed vendor selection, it addresses real-world assay challenges and offers actionable recommendations for reproducible, high-quality experiments.

• E-64: Potent L-trans-epoxysuccinyl Peptide Cysteine Protease

  2026-08-03

  E-64 is a highly specific, irreversible L-trans-epoxysuccinyl peptide inhibitor of cysteine proteases. It achieves low nanomolar IC50s against mammalian cathepsins and calpain, making it a gold standard for mechanistic and quantitative enzyme studies. APExBIO’s E-64 (A2576) is widely used in research on cancer, cell death, and protease signaling.

• Applied Workflows with Cy3 Goat Anti-Human IgG (H+L) Antibod

  2026-08-03

  The Cy3 Goat Anti-Human IgG (H+L) Antibody transforms immunoassay workflows by delivering unmatched sensitivity and multiplexing. Here, we dissect real-world experimental setups, advanced troubleshooting, and the direct research impact of this Cy3 conjugated secondary antibody—empowering translational immunologists and assay developers.

16505 records 1/1101 page Next 12345 下5页 Last page